Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
41 participants
OBSERVATIONAL
2006-04-03
2014-07-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Microperfusion is based on the exchange of substances across tiny holes of a small plastic tube called a "probe," which is inserted after numbing the skin over a fat pad. Through these openings, the fat pad is continuously rinsed with small amounts of fluid, and an exchange of substances occurs. The fluid drips from the other opening of the probe and is collected in a vial. Small amounts of study drugs are infused and the amount of substances released by the fat pad in response to them are measured.
Healthy normal volunteers 18 years of age and older may be eligible for this study. Candidates are screened with a medical history, physical examination and blood tests.
Participants undergo microperfusion. A needle is placed in an arm vein for collecting blood samples before and at the end of the experiment for measuring thyroid hormones and other substances in the blood. The skin over the fat pad next to the umbilicus (navel) is numbed and two microperfusion probes are inserted. A salt water solution is infused into the fat pad for one hour and the substances in the fluid are measured as the fluid leaves the fat pad. After 1 hour isoproterenol, a drug that aids in energy production by fat, is added to help determine the level of fat metabolism. After an additional hour small amounts of thyroid hormone are added to the fluid and samples are collected as they leave the body. Two catheters are inserted during each experiment. Small volumes of sterile fluid are circulated continuously in the tubing and samples are collected at regular intervals.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Healthy volunteers 18 years of age and older may be eligible for this study. Candidates are screened with a medical history, physical examination, and blood tests. Subjects with hyperlipidemia, impaired glucose tolerance or diabetes and thyroid disease are not eligible for the participation in this study. Qualifying study participants undergo subcutaneous fat tissue microdialysis to assess the effects of T3 and T4 on the activity of fat tissue. The medications isoproterenol and T3 or T4 are injected in fat tissue under the skin of the abdomen, and fluid samples are collected from the area over a 6-12 hour period using the same small needle. Glycerol is then measured to study how the thyroid hormones affect fat metabolism. During this procedure a 10% glucose solution is infused through the catheter in the arm to limit lipolysis due to fasting. Four different sets of experiments are performed with different thyroid hormone doses and/or durations.
These experiments will provide new information on the role of thyroid hormone in the regulation of adipose tissue metabolism and will help in identifying new treatments for the management of obesity.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Written informed consent.
Exclusion Criteria
* Blood pressure greater than 140/90 mmHg \[17\] or current antihypertensive therapy
* History of cardiovascular disease
* BMI less than or equal to 20 or greater than or equal to 30 Kg/m(2).
* Diabetes mellitus (serum glucose greater than or equal to 126 mg/dL).
* Hypercholesterolemia (serum levels greater than or equal to 240 mg/dL), hypertriglyceridemia (plasma levels greater than or equal to 220 mg/dL) and/or use of antilipemic therapy.
* Liver disease or ALT serum level greater than two fold the upper laboratory reference limit.
* Renal insufficiency or estimated creatinine clearance less than or equal to 50 mL/min (Cockcroft method).
* History of illicit drug or alcohol abuse within the last 5 years; current use of drugs (by history) or alcohol (CAGE greater than 3).
* Psychiatric conditions or behavior that would be incompatible with safe and successful participation in this study
* Current use of medications/dietary supplements/alternative therapies known to alter thyroid function.
* Allergy to ethanol, levothyroxine, liothyronine, isoproterenol, lidocaine.
* Pregnancy/breastfeeding.
* Current smoker
All subjects will be fully informed of the aim, nature, and risks of the study prior to giving written informed consent.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Francesco S Celi, M.D.
Role: PRINCIPAL_INVESTIGATOR
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Elks ML, Manganiello VC. Effects of thyroid hormone on regulation of lipolysis and adenosine 3',5'-monophosphate metabolism in 3T3-L1 adipocytes. Endocrinology. 1985 Sep;117(3):947-53. doi: 10.1210/endo-117-3-947.
Germack R, Starzec A, Perret GY. Regulation of beta 1- and beta 3-adrenergic agonist-stimulated lipolytic response in hyperthyroid and hypothyroid rat white adipocytes. Br J Pharmacol. 2000 Feb;129(3):448-56. doi: 10.1038/sj.bjp.0703008.
Mentuccia D, Proietti-Pannunzi L, Tanner K, Bacci V, Pollin TI, Poehlman ET, Shuldiner AR, Celi FS. Association between a novel variant of the human type 2 deiodinase gene Thr92Ala and insulin resistance: evidence of interaction with the Trp64Arg variant of the beta-3-adrenergic receptor. Diabetes. 2002 Mar;51(3):880-3. doi: 10.2337/diabetes.51.3.880.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
06-DK-0133
Identifier Type: -
Identifier Source: secondary_id
060133
Identifier Type: -
Identifier Source: org_study_id